Delayed
Nasdaq
03:58:52 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
47.19
USD
|
-0.67%
|
|
-3.41%
|
+340.35%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
821
|
547.2
|
495.2
|
2,463
|
-
|
-
|
Enterprise Value (EV)
1 |
821
|
547.2
|
495.2
|
2,463
|
2,463
|
2,463
|
P/E ratio
|
-14.2
x
|
-8.66
x
|
-8.13
x
|
-34.6
x
|
-28.1
x
|
-22.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
226
x
|
63.5
x
|
61.3
x
|
784
x
|
1,209
x
|
237
x
|
EV / Revenue
|
226
x
|
63.5
x
|
61.3
x
|
784
x
|
1,209
x
|
237
x
|
EV / EBITDA
|
-25
x
|
-8.26
x
|
-6.97
x
|
-24.5
x
|
-20.8
x
|
-
|
EV / FCF
|
-44.5
x
|
-8.16
x
|
-
|
-57.2
x
|
-24.5
x
|
-21.6
x
|
FCF Yield
|
-2.25%
|
-12.3%
|
-
|
-1.75%
|
-4.08%
|
-4.62%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
41,612
|
41,551
|
46,151
|
51,845
|
-
|
-
|
Reference price
2 |
19.73
|
13.17
|
10.73
|
47.51
|
47.51
|
47.51
|
Announcement Date
|
3/18/22
|
3/10/23
|
3/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
3.637
|
8.612
|
8.083
|
3.141
|
2.038
|
10.38
|
EBITDA
1 |
-
|
-32.82
|
-66.25
|
-71.02
|
-100.3
|
-118.6
|
-
|
EBIT
1 |
-
|
-32.93
|
-67.09
|
-72.98
|
-93.46
|
-117.4
|
-141.8
|
Operating Margin
|
-
|
-905.39%
|
-779.04%
|
-902.87%
|
-2,975.63%
|
-5,761.41%
|
-1,365.52%
|
Earnings before Tax (EBT)
1 |
-
|
-32.67
|
-63.06
|
-59.29
|
-68.99
|
-96.97
|
-126
|
Net income
1 |
-6.784
|
-32.67
|
-63.06
|
-59.29
|
-74.31
|
-97.55
|
-126
|
Net margin
|
-
|
-898.32%
|
-732.22%
|
-733.55%
|
-2,365.78%
|
-4,787.84%
|
-1,213.2%
|
EPS
2 |
-7.416
|
-1.390
|
-1.520
|
-1.320
|
-1.372
|
-1.691
|
-2.093
|
Free Cash Flow
1 |
-
|
-18.46
|
-67.09
|
-
|
-43.07
|
-100.4
|
-113.8
|
FCF margin
|
-
|
-507.51%
|
-779.04%
|
-
|
-1,371.17%
|
-4,927.61%
|
-1,095.99%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/16/21
|
3/18/22
|
3/10/23
|
3/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1.616
|
1.589
|
2.365
|
1.813
|
2.845
|
2.048
|
1.057
|
2.517
|
2.461
|
1.252
|
0.6342
|
0.7095
|
0.5833
|
-
|
-
|
EBITDA
|
-13.43
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-15.61
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-13.49
|
-13.54
|
-17.26
|
-18.02
|
-18.27
|
-20.28
|
-20.75
|
-15.81
|
-16.14
|
-20.16
|
-22.58
|
-23.9
|
-25.73
|
-
|
-
|
Operating Margin
|
-834.78%
|
-852.23%
|
-729.85%
|
-994.04%
|
-642.04%
|
-990.28%
|
-1,962.91%
|
-628.25%
|
-655.71%
|
-1,610.3%
|
-3,560.07%
|
-3,368.76%
|
-4,410.26%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-13.42
|
-13.41
|
-16.89
|
-16.7
|
-16.06
|
-17.46
|
-17.51
|
-11.57
|
-11.76
|
-14.76
|
-14.53
|
-15.32
|
-16.74
|
-
|
-
|
Net income
1 |
-13.42
|
-13.41
|
-16.89
|
-16.7
|
-16.06
|
-17.46
|
-17.51
|
-11.57
|
-11.76
|
-14.76
|
-16.89
|
-17.75
|
-19.87
|
-
|
-
|
Net margin
|
-830.2%
|
-843.93%
|
-714.08%
|
-920.9%
|
-564.67%
|
-852.49%
|
-1,656.39%
|
-459.59%
|
-477.77%
|
-1,178.91%
|
-2,663.85%
|
-2,501.77%
|
-3,406.37%
|
-
|
-
|
EPS
2 |
-0.2900
|
-0.3200
|
-0.4100
|
-0.4000
|
-0.3900
|
-0.4200
|
-0.4200
|
-0.2500
|
-0.2500
|
-0.3000
|
-0.3200
|
-0.3460
|
-0.3880
|
-0.3350
|
-0.3525
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/18/22
|
5/10/22
|
8/9/22
|
11/10/22
|
3/10/23
|
5/9/23
|
8/8/23
|
11/7/23
|
3/8/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-18.5
|
-67.1
|
-
|
-43.1
|
-100
|
-114
|
ROE (net income / shareholders' equity)
|
-
|
-18.6%
|
-18.4%
|
-
|
-18.3%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-
|
-0.7200
|
-1.040
|
-
|
-1.020
|
-0.7100
|
-1.170
|
Capex
1 |
-
|
-
|
-
|
-
|
1.7
|
1.83
|
1.9
|
Capex / Sales
|
-
|
-
|
-
|
-
|
54.12%
|
89.57%
|
18.3%
|
Announcement Date
|
4/16/21
|
3/18/22
|
3/10/23
|
3/8/24
|
-
|
-
|
-
|
Last Close Price
47.51
USD Average target price
63.57
USD Spread / Average Target +33.81% Consensus |
1st Jan change
|
Capi.
|
---|
| +340.35% | 2.46B | | +33.59% | 50.85B | | +0.01% | 42.82B | | +49.62% | 42.03B | | -4.96% | 29.55B | | +11.15% | 26.11B | | -21.93% | 19.13B | | +8.40% | 13.05B | | +28.18% | 12.16B | | +24.69% | 12.08B |
Other Biotechnology & Medical Research
|